

BIBLIOGRAPHIE

- [1] Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. *Muscle Nerves* 2008;37:141–9.
- [2] Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *Lancet Neurol* 2009;8:475–90.
- [3] Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia gravis: from autoantibodies to therapy. *Curr Opin Neurol* 2018;31:517–25.
- [4] Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. *J Neurol* 2009;256:1314–20.

- [5] Evoli A. Myasthenia gravis: new developments in research and treatment. *Curr Opin Neurol* 2017;30:464–70.
- [6] Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. *Nat Clin Pract Neurol* 2008;4:317–27.
- [7] Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. *N Engl J Med* 2016;375:511–22.
- [8] Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. *Muscle Nerves* 2000;23:1137–44.
- [9] Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton Myasthenic Syndrome. *Neurol Clin* 2018;36:379–94.